The role of fibric acids in atherosclerosis.

被引:148
作者
Fruchart J.C. [1 ]
Staels B. [1 ]
Duriez P. [1 ]
机构
[1] Inserm U325, Départment d' Athérosclérose, Institut Pasteur et Université de Lille, Lille
关键词
Fenofibrate; Bezafibrate; Fenofibric Acid; Minimum Lumen Diameter; Ciprofibrate;
D O I
10.1007/s11883-001-0015-x
中图分类号
学科分类号
摘要
The hypolipidemic fibric acid drugs are peroxisome proliferator-activated receptor a (PPAR alpha) ligands. PPAR alpha activated by fibric acids form heterodimers with the 9-cis retinoic acid receptor (RXR). The PPAR/RXR heterodimers bind to peroxisome proliferator response elements (PPRE), which are located in numerous gene promoters and increase the level of the expression of mRNAs encoded by PPAR alpha target genes. Fibric acids decrease triglyceride plasma levels through increases in the expression of genes involved in fatty acid-beta oxidation. Furthermore, they decrease triglycerides by increasing lipoprotein lipase gene expression and by decreasing apolipoprotein C-III gene expression. Fibric acids increase high-density lipoprotein (HDL) cholesterol partly by increasing apolipoprotein A-I and apolipoprotein A-II gene expression. Fibric acids also reduce vascular wall inflammation and the expression of genes involved in different vascular functions (ie, vasomotricity, thrombosis). Fibric acids are used to treat primary hypertriglyceridemia and mixed hyperlipidemia. Some fibric acid molecules are active in essential hypercholesterolemia. Clinical evidence shows that fibric acids reduce coronary atherosclerosis progression in dyslipidemic patients (eg, bezafibrate, gemfibrozil) and in type 2 diabetic patients (fenofibrate). Gemfibrozil decreases coronary morbidity and mortality in patients with low HDL cholesterol, normal triglycerides,and normal low-density lipoprotein (LDL) cholesterol plasma levels. Further clinical studies are necessary to investigate if fibric acids decrease cardiovascular mortality in type 2 diabetes and in primary prevention of hypertriglyceridemia and hypolipidemia.
引用
收藏
页码:83 / 92
页数:9
相关论文
共 201 条
  • [31] Acosta E(1999)Randomized crossover study of gemfibrozil versus lovastatin in familial combined hyperlipidemia: additive effects of combination treatment on lipid regulation Metabolism 48 47-54
  • [32] Ortiz JA(1996)Multicenter comparison of micronized fenofibrate and simvastatin in patients with primary type IIA or IIB hyperlipoproteinemia J Cardiovasc Pharmacol 27 563-570
  • [33] Kelly LJ(1996)Effects of regular and extended-release gemfibrozil on plasma lipoproteins and apolipoproteins in hypercholesterolemic patients with decreased HDL cholesterol levels Atherosclerosis 127 113-122
  • [34] Vicario PP(1985)Effects of fenofibrate on high and low density lipoprotein metabolism in heterozygous familial hypercholesterolemia Atherosclerosis 55 161-169
  • [35] Thompson GM(1992)Fibrates influence the expression of genes involved in lipoprotein metabolism in a tissue-selective manner in the rat Arterioscler Thromb 12 286-294
  • [36] Kesaniemi YA(1995)Regulation of rat liver apolipoprotein A-I, apolipoprotein A-II and acyl-coenzyme A oxidase gene expression by fibrates and dietary fatty acids Eur J Biochem 232 179-187
  • [37] Grundy SM(1994)Negative regulation of the human apolipoprotein A-I promoter by fibrates can be attenuated by the interaction of the peroxisome proliferator-activated receptor with its response element J Biol Chem 269 31012-31018
  • [38] Hahn SE(1996)Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice J Clin Invest 97 2408-2416
  • [39] Goldberg DM(1998)Fibrate-modulated expression of fibrinogen, plasminogen activator inhibitor-1 and apolipoprotein A-I in cultured cynomolgus monkey hepatocytes: role of the peroxisome proliferator-activated receptor-alpha Thromb Haemost 80 942-948
  • [40] Desager JP(1999)Beneficial effects of fibrates on apolipoprotein A-I metabolism occur independently of any peroxisome proliferative response Circulation 99 2445-2451